Pharma industry weight behind making daily oral contraceptives available OTC in the US gains substantial heft with Perrigo Company PLC’s planned acquisition of French firm HRA Pharma, which recently received UK approval for nonprescription sales of a daily-use progestin-only contraceptive.
With its acquisition of HRA, officially identified in France as Héra SAS, for €1.8bn ($2.1bn) in a cash deal announced...